Abstract
In recent years, metabolomics has attracted great scientific attention. The metabolomics methodology might permit a view into transitional phases between healthy liver and nonalcoholic steatohepatitis. Metabolomics can help to analyze the metabolic alterations that play a main role in the progression of nonalcoholic steatohepatitis. Lipid, glucose, amino acid, and bile acid metabolism should be widely studied to understand the complex pathogenesis of nonalcoholic steatohepatitis. The discovery of new biomarkers would be important for diagnosis and staging of liver disease as well as for the assessment of efficacy of new drugs. Here, we review the metabolomics data regarding nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. We analyzed the main studies regarding the application of metabolomics methodology in the complex context of nonalcoholic steatohepatitis, trying to create a bridge from the basic to the clinical aspects.
Highlights
Nonalcoholic fatty liver disease (NAFLD) represents the most common cause of chronic liver disease in the Western countries [1]
We examined some crucial metabolic pathways involved in liver disease, including altered key metabolic pathways such as cellular energy metabolism, lipid and glucose metabolism, amino acid pathways, metabolism of bile acids (BAs), and oxidative stress
(1) Deoxycholic acid was higher in NAFLD versus normal liver; (2) antioxidative ether glycerophospholipids, sn-2 arachidonly diacylglycerophosphocholine, and free arachidonic acid were different between nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH)
Summary
Nonalcoholic fatty liver disease (NAFLD) represents the most common cause of chronic liver disease in the Western countries [1]. The lack of a widely approved therapeutic approach represents another major concern. There are noteworthy limits concerning efficacy and long-term safety [2] In this scenario, the discovery of new biomarkers of NAFLD/NASH useful for diagnosis, staging, and assessment of efficacy of new drugs is an important scientific goal. Metabolomics might be an interesting tool for this aim since it can be applied for the early diagnosis of liver disease, for better understanding the pathogenesis, and for the development of new drugs [9]. Metabolomics represents a new and powerful technology for biomarker detection within a dynamic field. The metabolomics approach might be useful for the early diagnosis of liver disease and for assessing the efficacy of new therapeutic interventions. We examined some crucial metabolic pathways involved in liver disease, including altered key metabolic pathways such as cellular energy metabolism, lipid and glucose metabolism, amino acid pathways, metabolism of bile acids (BAs), and oxidative stress
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
